1. Critical appraisal of “Goetz G, Wernly B, Wild C (2023) Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and safety;Nürnberg;IJC Heart Vasc.,2023
2. Anxiety, depression and quality of life in acute high-risk cardiac disease patients eligible for wearable cardioverter defibrillator: results from the prospective multicenter CREDregistry;Weiss;PLoS One,2019
3. (2018) Wearable Cardioverter-defibrillator after Myocardial Infarction;Olgin;N. Engl. J. Med.,2018
4. Goetz G., Wernly B., Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022. Decision Support Document 103/ 2. Update 2022.: 2022 [cited 24.10.2022]. Available from: https://eprints.aihta.at/1407/.
5. GRADE guidelines: 3. rating the quality of evidence;Balshem;J. Clin. Epidemiol.,2011